<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157958</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-DEB-201</org_study_id>
    <nct_id>NCT05157958</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa</brief_title>
  <official_title>Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After confirming eligibility, a single subject with two selected target lesions will receive&#xD;
      both ALLO-ASC-SHEET and Vehicle control, one target lesion for each IP (one target lesion for&#xD;
      ALLO-ASC-SHEET and the other target for Vehicle control), and which lesion to apply which IP&#xD;
      will be determined randomly at the time of enrollment using IWRS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ALLO-ASC-SHEET versus matching control</measure>
    <time_frame>First application to week 37</time_frame>
    <description>Incidence, severity, relationship of adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of complete wound closure</measure>
    <time_frame>First application to week 17</time_frame>
    <description>Proportion of subject with target skin ulcer area meeting the definition of wound closure at 5 weeks after the completion of treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-SHEET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic mesenchymal stem cells&#xD;
Dressing for Dystrophic Epidermolysis Bullosa wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrogel Sheet&#xD;
Matching control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-SHEET</intervention_name>
    <description>Weekly administration</description>
    <arm_group_label>ALLO-ASC-SHEET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Control</intervention_name>
    <description>Weekly administration</description>
    <arm_group_label>Conventional Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subject diagnosed as dystrophic epidermolysis bullosa confirmed by clinical criteria&#xD;
             and one of the following:&#xD;
&#xD;
               1. Immunostaining test: patients who have reduced or no type 7 collagen in staining&#xD;
                  degree of immunofluorescence. Other antigens (laminin-332, type 17 collagen,&#xD;
                  plectin, integrin α6β4, type 5 and type 14 keratin, etc.) are normal in&#xD;
                  immune-staining.&#xD;
&#xD;
               2. COL7A1 mutational analysis: confirmation of COL7A1 genetic mutation.&#xD;
&#xD;
          2. Subject with skin ulcer lesions of dystrophic epidermolysis bullosa meet the following&#xD;
             criteria, on the screening start day (Visit 1) and treatment start day (enrollment&#xD;
             day) (Visit 3):&#xD;
&#xD;
               1. Subject has two skin ulcer lesions judged as comparable to compare the safety and&#xD;
                  efficacy by investigator during screening period and prior to the IP application&#xD;
                  (enrollment day).&#xD;
&#xD;
               2. Two skin ulcer lesions meeting criteria stated in 2a) should be sized 5-20 cm2&#xD;
                  (inclusive)&#xD;
&#xD;
          3. Subject who has two comparable target skin ulcer lesions, and each lesions with a&#xD;
             change of size equal to or less than ±50% at treatment day (Visit 3) compared to that&#xD;
             of screening day (Visit 1)&#xD;
&#xD;
          4. Subject who has no clinical evidence of infection related signs/symptoms, or visible&#xD;
             necrosis in the target skin ulcer area (area including ulcer lesion and surrounding&#xD;
             area where the IP is to be applied).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Subject who requires antibiotics due to bacterial infection on skin of the target skin&#xD;
             ulcer area (area including ulcer lesion and surrounding area where the IP is to be&#xD;
             applied).&#xD;
&#xD;
          2. Female subjects: pregnant woman (indicated by serum hCG test result at screening),&#xD;
             breast-feeding patient, all sexually active patient, with child bearing potential in&#xD;
             case of female*, who is not willing to contracept** during the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

